Muscle wasting is associated with reduced exercise capacity and advanced disease in patients with chronic heart failure

Future Cardiology

Volumn 9, Issue 6, 2013, Pages 767-770

  Kato, Akihiko ^a  

^a HAMAMATSU UNIVERSITY HOSPITAL   (Japan)

Author keywords

chronic heart failure; exercise capacity; left ventricular ejection fraction; muscle strength; muscle wasting

Indexed keywords

AGED; COMORBIDITY; DISEASE COURSE; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FEMALE; GAIT; HAND GRIP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE ATROPHY; MUSCLE MASS; MUSCLE STRENGTH; NOTE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; TREADMILL; WALKING SPEED;

FEMALE; HEART FAILURE; HUMANS; MALE; MUSCULAR DYSTROPHIES;

EID: 84887215554     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.13.74     Document Type: Note

References (24)

1. Mancini DM, Walter G, Reichek N et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 85, 1364-1373 (1992).
2. Anker SD, Ponikowski PP, Clark AL et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur. Heart J. 20, 683-693 (1999).
3. Anker SD, Swan JW, Volterrani M et al. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur. Heart J. 18, 259-269 (1997).
4. Fülster S, Tacke M, Sandek A et al. Muscle wasting in patients with chronic heart failure: Results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur. Heart J. 34, 512-519 (2013).
5. Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. Sarcopenia: European consensus on definition and diagnosis. Age Ageing 39, 412-423 (2010).
6. Anker SD, Ponikowski P, Varney S et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349, 1050-1053 (1997).
7. Landi F, Lipertoni R, Russo A et al. Sarcopenia as a risk factor for falls in elderly individuals. Results from the iISIRENTE study. Clin. Nutr. 31, 652-658 (2012).
8. Landi F, Cruz-Jentoft AJ, Liperoti R et al. Sarcopenia and mortality risk in frail older persons aged 80 years and older: Results from iISIRENTE study. Age Ageing 42, 203-209 (2913).
9. Gerber Y, Melton LJ, Weston SA et al. Osteoporotic fractures and heart failure in the community. Am. J. Med. 124, 418-425 (2011).
10. Janssen SP, Gayen-Ramirez G, Van Ven Bergh A et al. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 111, 996-1005 (2005).
11. Schaap LA, Saskia MF, Deeg DJH et al. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am. J. Med. 119, 526.e9-526.e17 (2006).
12. Jug B, Salobir BG, Vene N et al. Interleukin-6 is a stronger prognostic predictor than high-sensitive C-reactive protein in patients with chronic stable heart failure. Heart Vessels 24, 271-276 (2009).
13. Venture-Clapier R, Mettauer B, Bigard X. Beneficial effects of endurance training on cardiac and skeletal muscle energy metabolism in heart failure. Cardiovasc. Res. 73, 10-18 (2007).
14. Gielen S, Sandri M, Kozarez I et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age. The randomized Leipzig exercise intervention in chronic heart failure and aging catabolism study. Circulation 125, 2716-2727 (2012).
15. Kitzman DW, Brubaker PH, Herrington DM et al. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: A randomized, controlled, single-blind trial. J. Am. Coll. Cardiol. doi:10.1016/j.jacc.04.033 (2013) (Epub ahead of print).
16. Breitbart A, Auger-Messier M, Molkentin JD et al. Myostatin from the heart: Local and systemic actions in cardiac failure and muscle wasting. Am. J. Physiol. Circ. Physiol. 300, H1973-H1982 (2011).
17. Heineke J, Auger-Messier M, Xu J et al. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 121, 419-425 (2010).
18. George I, Bish LT, Kamalakkannan G et al. Myostatin activation in patients with advanced heart failure and after mechanical loading. Eur. J. Heart Fail. 12, 443-453 (2010).
19. Gruson D, Ahn SA, Ketelslegers JM et al. Increase plasma myostatin in heart failure. Eur. J. Heart Fail. 13, 734-736 (2011).
20. Attie KM, Borgstein NG, Yang Y et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve 47, 416-423 (2013).
21. Lenk K, Schur R, Linke A et al. Impact of exercise training on myostatin expression in myocardium and skeletal muscle in a chronic heart failure model. Eur. J. Heart Fail. 11, 342-348 (2009).
22. Shyu KG, Lu MJ, Wang BW et al. Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure. Eur. J. Clin. Invest. 36, 713-719 (2006).
23. Rozentryt P, Von Haehling S, Lainscak M et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: A randomized, double-blind pilot study. J. Cachexia Sarcopenia Muscle 1, 35-42 (2010).
24. Masson S, Marchioli R, Mozaffarian D et al. Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: Relation with fish intake, circulating biomarker, and mortality. Am. Heart J. 165, 208-214 (2013).